- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02890069
A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability and Pharmacodynamics (PD) of PDR001 in Combination With LCL161, Everolimus (RAD001) or Panobinostat (LBH589)
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Jena, Germany, 07740
- Novartis Investigative Site
-
Ulm, Germany, 89081
- Novartis Investigative Site
-
Wuerzburg, Germany, 97080
- Novartis Investigative Site
-
-
-
-
-
Seoul, Korea, Republic of, 03080
- Novartis Investigative Site
-
-
Korea
-
Seoul, Korea, Korea, Republic of, 05505
- Novartis Investigative Site
-
-
-
-
-
Amsterdam, Netherlands, 1066 CX
- Novartis Investigative Site
-
Leiden, Netherlands, 2300 RC
- Novartis Investigative Site
-
Rotterdam, Netherlands, 3075 EA
- Novartis Investigative Site
-
Utrecht, Netherlands, 3584CX
- Novartis Investigative Site
-
-
-
-
-
Madrid, Spain, 28041
- Novartis Investigative Site
-
-
Catalunya
-
Barcelona, Catalunya, Spain, 08035
- Novartis Investigative Site
-
-
Navarra
-
Pamplona, Navarra, Spain, 31008
- Novartis Investigative Site
-
-
-
-
-
Taipei, Taiwan, 10002
- Novartis Investigative Site
-
-
-
-
-
Manchester, United Kingdom, M20 4BX
- Novartis Investigative Site
-
Oxford, United Kingdom, OX3 7LJ
- Novartis Investigative Site
-
-
Surrey
-
Sutton, Surrey, United Kingdom, SM2 5PT
- Novartis Investigative Site
-
-
-
-
California
-
Santa Monica, California, United States, 90404
- UCLA Santa Monica Hematology / Oncology SC
-
-
Maryland
-
Baltimore, Maryland, United States, 21231
- Sidney Kimmel Comprehensive Cancer Center
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- The Regents of the University of Michigan
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University Medical School SC
-
-
Texas
-
Houston, Texas, United States, 77030
- University of Texas MD Anderson Cancer Center
-
San Antonio, Texas, United States, 78229
- UT Health San Antonio Mays Cancer Center
-
-
Utah
-
Salt Lake City, Utah, United States, 84112
- Huntsman Cancer Institute
-
-
Washington
-
Seattle, Washington, United States, 98105
- Seattle Cancer Care Alliance
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Written informed consent prior to any procedure
Patients with advanced/metastatic cancer, with measurable disease as determined by RECIST version 1.1, who have progressed despite standard therapy or are intolerant to SOC, or for whom no standard therapy exists. Patients must fit into one of the following groups:
• CRC •NSCLC • TNBC• RCC
- ECOG ≤ 2
- Patient must have a site of disease for biopsy, and be a candidate for tumor biopsy according to the institution's guidelines. Patient must be willing to undergo a new tumor biopsy at screening, and again during therapy on this study.
- Prior therapy with PD-1/PDL-1 inhibitors is allowed provided any toxicity attributed to prior PD-1- or PD-L1-directed therapy did not lead to discontinuation of therapy.
Exclusion Criteria:
- Presence of symptomatic central nervous system (CNS) metastases, or CNS metastases that require local CNS-directed therapy within prior 2 weeks.
- Patients with known hypersensitivity to any of the components of an investigational treatment will be excluded from participation in the corresponding arm but are eligible for participation in other study arm; Patients that have a history of hypersensitivity to rapamycin derivatives will be excluded from participation in the everolimus arm
- History of or current drug-induced interstitial lung disease or pneumonitis grade ≥2
- Out of range lab values as defined in protocol
- Impaired cardiac function or clinically significant cardiac disease
- Active, known or suspected autoimmune disease
- Human Immunodeficiency Virus (HIV), or active Hepatitis C (HCV) virus. Escalation: active Hepatitis B (HBV); Expansion: Patients with Chronic HBV currently on medication will not be excluded.
- Impairment of gastrointestinal (GI) function
- Malignant disease, other than that being treated in this study
- Systemic anti-cancer therapy within 2 weeks of the first dose of study treatment. For cytotoxic agents that have major delayed toxicity and washout period is 6 weeks; prior immunotherapy - washout is 4 weeks
- Active infection requiring systemic antibiotic therapy.
- Patients requiring chronic treatment with systemic steroid therapy, other than replacement dose steroids or treatment with low, stable dose of steroid (<10 mg/day prednisone or equivalent) for stable CNS metastatic disease.
- Patients receiving systemic treatment with any immunosuppressive medication.
- Major surgery within 2 weeks of the first dose of study treatment
- Radiotherapy within 2 weeks of the first dose of study drug
- Participation in an interventional, investigational study within 2 weeks of the first dose of study treatment.
- Presence of ≥ CTCAE grade 2 toxicity (except alopecia, peripheral neuropathy and ototoxicity, which are excluded if ≥ CTCAE grade 3) due to prior therapy.
- Use of hematopoietic colony stimulating growth factors </= 3 weeks prior to first dose
Additional exclusion criteria for PDR001/LCL161
- Patients requiring medications metabolized through CYP3A4/5 and have a narrow therapeutic index or medications that are CYP3A4 substrates that cause QT prolongation
- Patients requiring treatment with strong CYP2C8 inhibitors
Additional exclusion criteria for PDR001/Everolimus
- Patients requiring treatment with moderate CYP3A4 inhibitors
- Patients requiring treatment with a strong CYP3A4 inhibitor or inducer
Additional exclusion criteria for PDR001/Panobinostat-
- Patient who received DAC inhibitors
- Patient needing valproic acid during the study or within 5 days prior to first dose
- Patients requiring medications that are sensitive CYP2D6 substrates areCYP2D6 substrates with a narrow therapeutic index or are anti-arrhythmic drugs/drugs with QT-prolongation risks
- Patients requiring a strong inhibitor or inducer of CYP3A4
- Clinically significant, uncontrolled heart disease and/or recent cardiac event within 6 months prior to study
- Unresolved diarrhea ≥ CTCAE grade 2 or a medical condition associated with chronic diarrhea
- Taking medications with QT prolongation risk or interval or inducing Torsade de pointes
Additional exclusion criteria for PDR001/QBM076-
- Patients requiring medications that are strong inducers or strong inhibitors of CYP3A4
- Patients requiring medications with narrow therapeutic index CYP3A4 substrates
- Women using any form of hormonal contraception (oral, injected, implanted, transdermal) will be excluded (unless they are willing to switch to another effective form of contraception under their physician's guidance)
Additional exclusion criteria for PDR001/HDM201-
- Prior treatment with compounds with the same mode of action as proposed for HDM201, i.e. an inhibition of the interaction of TP53 with HDM2, e.g. RG7112 or CGM097
- Patients who require the following treatments moderate to strong CYP3A4 inhibitors; any substrates of CYP3A4/5 with a narrow therapeutic index
- Moderate to strong CYP3A4 inducers
- Patients having out of range values for:
Absolute neutrophil count (ANC) <1500/µL; Platelets < 100 000/µL
Other protocol-defined inclusion exclusion criteria may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CRC - PDR001 + LCL161
Enrollment to this combination arm is closed to further enrollment.
|
anti-PD1 antibody
|
Experimental: NSCLC - PDR001 + LCL161
Enrollment to this combination arm is closed to further enrollment.
|
anti-PD1 antibody
|
Experimental: TNBC - PDR001 + LCL161
Enrollment to this combination arm is closed to further enrollment.
|
anti-PD1 antibody
|
Experimental: CRC - PDR001+ Everolimus
Enrollment to this combination arm is closed to further enrollment.
|
Other Names:
anti-PD1 antibody
|
Experimental: NSCLC - PDR001+ Everolimus
Enrollment to this combination arm is closed to further enrollment.
|
Other Names:
anti-PD1 antibody
|
Experimental: TNBC - PDR001+ Everolimus
Enrollment to this combination arm is closed to further enrollment.
|
Other Names:
anti-PD1 antibody
|
Experimental: CRC - PDR001 + Panobinostat
Enrollment to this combination arm is closed to further enrollment.
|
Other Names:
anti-PD1 antibody
|
Experimental: NSCLC - PDR001 + Panobinostat
Enrollment to this combination arm is closed to further enrollment.
|
Other Names:
anti-PD1 antibody
|
Experimental: TNBC - PDR001 + Panobinostat
Enrollment to this combination arm is closed to further enrollment.
|
Other Names:
anti-PD1 antibody
|
Experimental: CRC - PDR001 + QBM076
Enrollment to this combination arm is closed to further enrollment.
|
|
Experimental: TNBC - PDR001 + QBM076
Enrollment to this combination arm is closed to further enrollment.
|
|
Experimental: NSCLC- PDR001 + QBM076
Enrollment to this combination arm is closed to further enrollment.
|
|
Experimental: CRC - PDR001 + HDM201
Dose escalation completed, expansion arm.
|
|
Experimental: RCC - PDR001 + HDM201
Dose escalation completed, expansion arm.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase 1: Incidence of dose limiting toxicities (DLTs)
Time Frame: 5.5 years
|
During the first two cycles Cycle = 28 days
|
5.5 years
|
Frequency of dose interruptions and reductions
Time Frame: 5.5 years
|
Through study completion, an average of 6 months
|
5.5 years
|
Frequency and severity of treatment-emergent adverse events (AEs) and serious adverse events (SAEs)
Time Frame: 6 years
|
Through study completion, an average of 6 months
|
6 years
|
Changes between baseline and post-baseline laboratory parameters and vital signs
Time Frame: 6 years
|
Through study completion, an average of 6 months
|
6 years
|
Dose intensities
Time Frame: 6 years
|
Through study completion, an average of 6 months
|
6 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes from baseline in ECG parameters in patients recieving PDR001 in combination with Panobinostat
Time Frame: 6 years
|
Baseline and end of treatment, an average of 6 months
|
6 years
|
Best overall response (BOR)
Time Frame: 6 years
|
per RECIST v1.1
|
6 years
|
Time to reach max concentration (Tmax) for PDR001
Time Frame: 6 years
|
6 years
|
|
Presence of anti-PDR001 antibodies
Time Frame: 6 years
|
6 years
|
|
Progression free survival (PFS)
Time Frame: 6 years
|
per RECIST v1.1
|
6 years
|
Treatment Free Survival (TFS)
Time Frame: 6 years
|
6 years
|
|
Maximum and minimum plasma concentrations of LCL161 (Cmax and Cmin)
Time Frame: 6 years
|
Cycle 1 through cycle 6 in treatment period 1, an average of 6 months
|
6 years
|
Maximum and minimum Plasma concentrations of everolimus (Cmax and Cmin)
Time Frame: 6 years
|
Cycle 1 through cycle 6 in treatment period 1, an average of 6 months
|
6 years
|
Maximum and minimum plasma concentrations of panobinostat (Cmax and Cmin)
Time Frame: 6 years
|
Cycle 1 through cycle 6 in treatment period 1, an average of 6 months
|
6 years
|
Concentration of anti-PDR001 antibodies
Time Frame: 6 years
|
Cycle 1 through cycle 6 in treatment period 1 and 2, an average of 6 months
|
6 years
|
Maximum and minimum serum concentration of PDR001 (Cmax and Cmin)
Time Frame: 6 years
|
Cycle 1 through cycle 6 in treatment period 1 and 2, an average of 6 months
|
6 years
|
Area under the concentration-time curve calculated to the last concentration point (AUClast) for PDR001, as applicable
Time Frame: 6 years
|
Cycle 1 through cycle 6 in treatment period 1 and 2, an average of 6 months
|
6 years
|
Progression free survival (PFS) per irRC
Time Frame: 6 years
|
6 years
|
|
Area under the concentration-time curve calculated to the last concentration point (AUClast) for LCL161, as applicable
Time Frame: 6 years
|
Cycle 1 through cycle 6 in treatment period 1, an average of 6 months
|
6 years
|
Time to reach max concentration (Tmax) for LCL161
Time Frame: 6 years
|
Cycle 1 through cycle 6 in treatment period 1, an average of 6 months
|
6 years
|
Time to reach max concentration (Tmax) for Everolimus
Time Frame: 6 years
|
Cycle 1 through cycle 6 in treatment period 1, an average of 6 months
|
6 years
|
Time to reach max concentration (Tmax) for Panobinostat
Time Frame: 6 years
|
Cycle 1 through cycle 6 in treatment period 1, an average of 6 months
|
6 years
|
Area under the concentration-time curve calculated to the last concentration point (AUClast) for Everolimus, as applicable
Time Frame: 6 years
|
Cycle 1 through cycle 6 in treatment period 1, an average of 6 months
|
6 years
|
Area under the concentration-time curve calculated to the last concentration point (AUClast) for Panobinostat, as applicable
Time Frame: 6 years
|
Cycle 1 through cycle 6 in treatment period 1, an average of 6 months
|
6 years
|
Maximum and minimum Plasma concentrations of QBM076 (Cmax and Cmin)
Time Frame: 6 years
|
Cycle 1 through cycle 6 in treatment period 1, an average of 6 months
|
6 years
|
Maximum and minimum Plasma concentrations of HDM201 (Cmax and Cmin)
Time Frame: 6 years
|
Cycle 1 through cycle 6 in treatment period 1, an average of 6 months
|
6 years
|
Time to reach max concentration (Tmax) for QBM076
Time Frame: 6 years
|
Cycle 1 through cycle 6 in treatment period 1, an average of 6 months
|
6 years
|
Time to reach max concentration (Tmax) for HDM201
Time Frame: 6 years
|
Cycle 1 through cycle 6 in treatment period 1, an average of 6 months
|
6 years
|
Area under the concentration-time curve calculated to the last concentration point (AUClast) for QBM076, as applicable
Time Frame: 6 years
|
Cycle 1 through cycle 6 in treatment period 1, an average of 6 months
|
6 years
|
Area under the concentration-time curve calculated to the last concentration point (AUClast) for HDM201, as applicable
Time Frame: 6 years
|
Cycle 1 through cycle 6 in treatment period 1, an average of 6 months
|
6 years
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Respiratory Tract Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lung Diseases
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Kidney Diseases
- Urologic Diseases
- Adenocarcinoma
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Breast Diseases
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Breast Neoplasms
- Kidney Neoplasms
- Carcinoma, Renal Cell
- Carcinoma, Non-Small-Cell Lung
- Triple Negative Breast Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Immune Checkpoint Inhibitors
- Histone Deacetylase Inhibitors
- Everolimus
- Spartalizumab
- Panobinostat
Other Study ID Numbers
- CPDR001X2102
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma
-
Memorial Sloan Kettering Cancer CenterRecruitingNon Small Cell Lung Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Metastatic Non-Small Cell Lung CarcinomaUnited States
-
The Methodist Hospital Research InstituteMerck Sharp & Dohme LLCCompletedMetastatic Non-small Cell Lung Cancer | Metastatic Triple-negative Breast CancerUnited States
-
National Cancer Institute (NCI)AstraZenecaActive, not recruitingMetastatic Lung Non-Small Cell Carcinoma | Pancreatic Ductal Adenocarcinoma | Advanced Malignant Solid Neoplasm | Unresectable Pancreatic Carcinoma | Metastatic Pancreatic Adenocarcinoma | Stage III Pancreatic Cancer AJCC v6 and v7 | Stage IV Pancreatic Cancer AJCC v6 and v7 | Stage IIIA Lung Non-Small... and other conditionsUnited States, Canada
-
AbbVieActive, not recruitingCancer | Advanced Solid Tumors | Metastatic Solid Tumors | Triple-Negative Breast Cancer (TNBC) | Non-small-cell-lung-cancer (NSCLC)United States, Australia, France, Israel, Spain, Taiwan
-
VastBiomeRecruitingRenal Cell Carcinoma | Non-Small-Cell Lung Carcinoma | Malignant Melanoma | Triple-Negative Breast CancerUnited States
-
Lyell Immunopharma, Inc.RecruitingAdvanced Breast Cancer | NSCLC | Non Small Cell Lung Cancer | Triple Negative Breast Cancer | Non-small Cell Lung Cancer | Advanced Lung Carcinoma | Non Small Cell Lung Cancer Metastatic | NSCLC Stage IV | Recurrent Breast Cancer | TNBC - Triple-Negative Breast Cancer | Relapsed Cancer | NSCLC, Recurrent | Recurrent... and other conditionsUnited States
-
PfizerTerminatedNon-Small Cell Lung Cancer | Triple-negative Breast CancerUnited States
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingNSCLC | Non Small Cell Lung Cancer | Triple Negative Breast Cancer | Non Small Cell Lung Cancer Metastatic | NSCLC Stage IV | TNBC - Triple-Negative Breast Cancer | NSCLC Stage IV Without EGFR/ALK MutationUnited States, Canada
-
Cofactor Genomics, Inc.Curebase Inc.RecruitingRenal Cell Carcinoma | Cervical Cancer | Hepatocellular Carcinoma | Colorectal Cancer | Triple Negative Breast Cancer | Small-cell Lung Cancer | Esophageal Squamous Cell Carcinoma | Urothelial Carcinoma | Cancer of Head and Neck | Lung Cancer, Nonsmall Cell | Gastroesophageal Junction AdenocarcinomaUnited States
-
GB006, Inc., a wholly owned subsidiary of Gossamer...Merck Sharp & Dohme LLCTerminatedRenal Cell Carcinoma | Hepatocellular Carcinoma | Pancreatic Adenocarcinoma | Gastric Adenocarcinoma | Triple Negative Breast Cancer | Non-small Cell Lung Cancer | Small-cell Lung Cancer | Castration-resistant Prostate Cancer | Head and Neck Squamous Cell Carcinoma | Esophageal Adenocarcinoma | Esophageal... and other conditionsUnited States, United Kingdom
Clinical Trials on Everolimus
-
Novartis PharmaceuticalsTerminatedHepatocellular CarcinomaHong Kong, Taiwan, Thailand
-
The Netherlands Cancer InstituteActive, not recruitingNeuroendocrine CarcinomasNetherlands
-
Novartis PharmaceuticalsCompletedLymphangioleiomyomatosis (LAM) | Tuberous Sclerosis Complex (TSC)United States, United Kingdom, Germany, Italy, Russian Federation, Netherlands, Japan, Canada, Poland, France, Spain
-
German Breast GroupNovartisTerminatedMetastatic Breast CancerGermany
-
University of LuebeckTerminatedCoronary Artery DiseaseGermany
-
Guangdong Provincial People's HospitalNovartisUnknownNeuroendocrine Tumors | Carcinoid TumorChina
-
Novartis PharmaceuticalsCompletedGastroenteropancreatic Neuroendocrine Tumor of the Pulmonary ot Gastroenteropancreatic SystemGermany
-
Novartis PharmaceuticalsTerminatedCarcinoma, Renal CellAustralia, Korea, Republic of
-
Centre Leon BerardSuspended
-
Leiden University Medical CenterUnknownHead and Neck CancerNetherlands